Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer Inc. today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President ...

Pfizer outlines 2025 R&D milestones and oncology growth opportunities Feb. 04, 2025 3:54 PM ET Pfizer Inc. (PFE) Stock, PFE:CA Stock AI-Generated Earnings Calls Insights 1 Comment ...

Pfizer is also advancing a robust pipeline of oncology candidates, with several entering late-stage development. By 2030, it expects to have eight or more blockbuster oncology medicines in its ...

(Reuters) -Pfizer said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and development, as the drugmaker faces pressure from investors to produce ...

to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant Infinity smart liquid biopsy platform. Under the multi-year collaboration agreement, Guardant ...

Pfizer to end heart, obesity drug development By Reuters September 29, 20089:28 PM PDTUpdated September 29, 2008 ...

Pfizer’s Oncology R&D organization will maintain its fully integrated structure with Roger Dansey, M.D. serving as Interim Chief Oncology Officer, reporting to Dr. Boshoff effective January 1, 2025.

Pfizer reported Q4 2024 revenue of $17.8 billion, with $13.7 billion from non-COVID products, reflecting 11% operational year-over-year growth. Key growth drivers included the Vyndaqel family ...